Navigoe Wealth Management’s Indivior Pharmaceuticals INDV Stock Holding History

Navigoe Wealth Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+1	New	+$36	﹤0.01%	775

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Navigoe Wealth Management's INDV Position: Q2 2026 in Review

Navigoe Wealth Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #775 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Navigoe Wealth Management held 1 share of Indivior Pharmaceuticals worth $0 as of Q2 2026.
Indivior Pharmaceuticals was a new Navigoe Wealth Management position in Q2 2026.
Indivior Pharmaceuticals made up ﹤0.01% of Navigoe Wealth Management's portfolio in Q2 2026, its #775 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Navigoe Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.